Citi analyst Joanne Wuensch initiated coverage of Edwards Lifesciences with a Buy rating and $252 price target. The analyst said the focus of the company is on their TAVR and TMTT franchises -- which she called large, growing market opportunities -- noting that the TAVR market is expected to increase to reach $7B in 2024 from $4B today and the TMTT market expected to reach $3B in 2024 from $1B estimated in 2021.

RBC Capital analyst Shagun Singh raised the firm's price target on Edwards Lifesciences to $101 from $95 and keeps an Outperform rating on the shares as part of a broader research note previewing Q1 earnings for Medical Devices. The sector fundamentals are "flashing positive signals" and the firm is expecting strong results, the analyst tells investors in a research note. RBC adds that sentiment on the stock is mostly positive heading into the Q1 earnings season as TAVR trends appear to be steady and as investors focus on the multi-billion TMTT - or Transcatheter Mitral and Tricuspid Therapies - opportunity that is yet to be meaningfully factored into estimates.